BVF Partners GLPGF Position
Exited5-Fund ConvergenceBVF Partners exited their position in GALAPAGOS NV (GLPGF) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
GLPGF is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout in 1174 days (Jul 1, 2029), making the timing of BVF's position particularly relevant.
About GALAPAGOS NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Full company profile →BVF Partners GLPGF Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -1,454,422 | $0 |
| Q1 2025 | Decreased | 1,454,422 | -115,000 | $36.5M |
| Q4 2024 | Held | 1,569,422 | — | $43.2M |
| Q3 2024 | Held | 1,569,422 | — | $45.2M |
| Q2 2024 | Decreased | 1,569,422 | -294,387 | $38.9M |
| Q1 2024 | Decreased | 1,863,809 | -51,300 | $60.0M |
| Q4 2023 | Held | 1,915,109 | — | $77.8M |
| Q3 2023 | Decreased | 1,915,109 | -250,000 | $66.2M |
| Q2 2023 | Held | 2,165,109 | — | $88.0M |
| Q1 2023 | New | 2,165,109 | +2,165,109 | $83.7M |
Frequently Asked Questions
Does BVF Partners own GLPGF?
No. BVF Partners exited their position in GALAPAGOS NV (GLPGF) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own GLPGF?
5 specialist biotech hedge funds currently hold GLPGF, including EcoR1 Capital, Tang Capital Management, Deerfield Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy GLPGF?
BVF Partners's position in GLPGF was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's GLPGF position increasing or decreasing?
BVF Partners completely exited their GLPGF position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GLPGFCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →